Comparison of Supraflex Cruz 60 μm Versus Ultimaster Tansei 80 μm Stent Struts in High Bleeding Risk PCI Patients: Study design and Rational of Compare 60/80 HBR trial

Valeria Paradies, Matteo Maurina, Pim Tonino, Sjoerd H. Hofma, Jeroen Vos, Jan Peter van Kuijk, Rohit M. Oemrawsingh, Amar Al Mafragi, Fabrizio Spano, Ron Pisters, Jawed Polad, Sander Ijsselmuiden, Maribel Madeira Cambero, Pieter C. Smits*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Web of Science)

Abstract

Up to 45% of patients who underwent percutaneous coronary intervention (PCI) may have a high bleeding risk (HBR), depending on the bleeding risk definition.1 This condition is often associated with an enhanced risk of thrombotic events with a negative impact on short- and long-term outcomes,2–8 making the choice of an appropriate antithrombotic regimen after PCI particularly challenging. Advances in stent technologies, in which the introduction of newer generations of thinner strut drug-eluting stents (DES), have significantly reduced the rate of thrombotic complications and may justify a shorter dual antiplatelet therapy (DAPT) duration. Both in vitro and in vivo studies have shown that local hemodynamic factors may critically affect the natural history of atherosclerosis. Strut thickness correlates with flow disturbances and endothelial shear stress. Flow separation within struts determines areas of recirculation with low endothelial shear stress which promotes local concentration of activated platelets.9 By mitigating inflammation, vessel injury, and neointimal proliferation, thin and streamlined struts have been associated with faster vascular healing and re-endothelization and have resulted in lower rates of thrombotic events after PCI.10 11 The use of thin strut and ultra-thin strut stents may lead to a favorable trade-off in bleeding and ischemic events in patients with HBR. However, dedicated studies evaluating the performance of thin strut versus ultrathin strut stents in patients with HBR are lacking.

Original languageEnglish
Pages (from-to)230-237
Number of pages8
JournalAmerican Journal of Cardiology
Volume206
DOIs
Publication statusPublished - 1 Nov 2023

Bibliographical note

Funding Information:
The COMPARE 60/80 HBR study is an investigator-initiated trial, sponsored by the Research Maatschap Cardiologen Rotterdam Zuid (Maasstad Hospital, Rotterdam, The Netherlands), which received an unrestricted research grant from Sahajanand Medical Technologies, Surat, India.

Publisher Copyright:
© 2023

Fingerprint

Dive into the research topics of 'Comparison of Supraflex Cruz 60 μm Versus Ultimaster Tansei 80 μm Stent Struts in High Bleeding Risk PCI Patients: Study design and Rational of Compare 60/80 HBR trial'. Together they form a unique fingerprint.

Cite this